OxyContin Revised Labeling Expects Less Abuse Via Injection, Snorting

There will be no generics of original OxyContin; FDA says it can no longer serve as a reference product because it has a greater abuse potential than the reformulation, where Purdue has secured particularly strong language regarding reducing intranasal abuse.